Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
Oncology Letters · 20.07.2023 · 26 (3)
DOI: 10.3892/ol.2023.13967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 20.07.2023. Verfasst von Ryotaro Ohkuma und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo 142-8555, Japan. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are among the most notable advances in cancer immunotherapy; however, reliable biomarkers for the efficacy of ICIs are yet to be reported. Programmed death (PD)-ligand 1 (L1)-expressing CD14+ monocytes are associated with shorter overall survival (OS) time in patients with cancer treated with anti-PD-1 antibodies. The present study focused on the classification of monocytes into three subsets: Classical, intermediate and non-classical. A total of 44 patients with different types of cancer treated with anti-PD-1 monotherapy (pembrolizumab or nivolumab) were enrolled in the present study. The percentage of each monocyte subset was investigated, and the percentage of cells expressing PD-L1 or PD-1 within each of the three subsets was further analyzed. Higher pretreatment classical monocyte percentages were correlated with shorter OS (r=-0.32; P=0.032), whereas higher non-classical monocyte percentages were correlated with a favorable OS (r=0.39; P=0.0083). PD-L1-expressing classical monocytes accounted for a higher percentage of the total monocytes than non-classical monocytes with PD-L1 expression. In patients with non-small cell lung cancer (NSCLC), a higher percentage of PD-L1-expressing classical monocytes was correlated with shorter OS (r=-0.60; P=0.012), which is similar to the observation for the whole patient cohort. Comparatively, higher percentages of non-classical monocytes expressing PD-L1 were significantly associated with better OS, especially in patients with NSCLC (r=0.60; P=0.010). Moreover, a higher percentage of non-classical monocytes contributed to prolonged progression-free survival in patients with NSCLC (r=0.50; P=0.042), with similar results for PD-L1-expressing non-classical monocytes. The results suggested that the percentage of monocyte subsets in patients with cancer before anti-PD-1 monotherapy may predict the treatment efficacy and prognosis. Furthermore, more classical monocytes and fewer non-classical monocytes, especially those expressing PD-L1, are involved in shortening OS time, which may indicate the poor efficiency of anti-PD-1 treatment approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo 142-8555, Japan.
- Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan.
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157-8577, Japan.
- Division of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan.
- Department of Pathology, Showa University School of Medicine, Tokyo 157-8577, Japan.
Zitieren
APA
Ohkuma, R., Fujimoto, Y., Ieguchi, K., Onishi, N., Watanabe, M., Takayanagi, D., Goshima, T., Horiike, A., Hamada, K., Ariizumi, H., Hirasawa, Y., Ishiguro, T., Suzuki, R., Iriguchi, N., Tsurui, T., Sasaki, Y., Homma, M., Yamochi, T., Yoshimura, K., …, & Wada, S. (2023). Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy. Oncology Letters, 26(3). https://doi.org/10.3892/ol.2023.13967
Vancouver
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, et al. Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy. Oncology Letters. 2023;26(3). doi:10.3892/ol.2023.13967
BibTeX
@article{Ohkuma2023,
author = {Ohkuma, Ryotaro and Fujimoto, Yuki and Ieguchi, Katsuaki and Onishi, Nobuyuki and Watanabe, Makoto and Takayanagi, Daisuke and Goshima, Tsubasa and Horiike, Atsushi and Hamada, Kazuyuki and Ariizumi, Hirotsugu and Hirasawa, Yuya and Ishiguro, Tomoyuki and Suzuki, Risako and Iriguchi, Nana and Tsurui, Toshiaki and Sasaki, Yosuke and Homma, Mayumi and Yamochi, Toshiko and Yoshimura, Kiyoshi and Tsuji, Mayumi and Kiuchi, Yuji and Kobayashi, Shinichi and Tsunoda, Takuya and Wada, Satoshi},
title = {Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy},
journal = {Oncology Letters},
year = {2023},
volume = {26},
number = {3},
doi = {10.3892/ol.2023.13967}
}
EUVIMED